跳至主要内容
临床试验/NCT02847845
NCT02847845Unknown不适用

A Clinical Study About Improvement of Chronic Fatigue After Taking Red Ginseng

Eun Jung Kim2 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2016年6月最近更新:
适应症

试验速览

阶段
不适用
发起方
Eun Jung Kim
入组人数
50
试验地点
2
主要终点
100mm visual analogue scale(VAS) about fatigue change

研究概览

简要总结

The purpose of this study is to verify the efficacy of taking red ginseng for chronic fatigue patient.

详细描述

Verify the efficacy and safety after taking red ginseng for chronic fatigue syndrome or idiopathic chronic fatigue patient. They were verified through not only survey like VAS change about fatigue, fatigue severity scale, Chalder fatigue severity questionnaire, SRI-short form , BDI , ISI EQ-5D-5L, ginseng subjective symptoms questionnaire but also an anti-oxidant test and a salivary cortisol test after 6 weeks after taking red ginseng or placebo drugs.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Supportive Care
盲法
Double (Participant, Investigator)

入排标准

年龄范围
19 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • At least 19 years of age, but below 65 years of age
  • A subject who appear repetitive or continuous fatigue of unknown cause.
  • A subject who has not abnormal findings of blood pressure, complete blood cell count(Hb, Hct, WBC, glucose), biochemical examination(AST, ALT, creatinine), thyroid gland function test(TSH, FT4), Urine test(Urine glucose, Urine protein), Chest X-ray, and ECG for causing fatigue
  • A subject who voluntarily agrees to participate and signs after listening to explanation for purpose and characteristic about this clinical trial

排除标准

  • A subject who has history or PI for chronic fatigue
  • A subject who takes this drug in 2 weeks : antidepressant drug, anti-anxiety drug,sleeping pill, an antihistamine etc.
  • Pregnant, lactating women or a subject who has plan pregnancy.
  • A subject who receive medical treatment or takes dietary supplement(vit B,C etc) for chronic fatigue in 2 weeks.
  • A subject who has night duty, shift work or heavy work
  • A subject who is judged as being not fit by a specialist

结局指标

主要结局

100mm visual analogue scale(VAS) about fatigue change

时间窗: at 1(screening),2(baseline),3(after 2 weeks of administration), 4(after 4 weeks of administration), 5(after 6 weeks of administration) and 6(follow up evaluation after 10 weeks of administration) visit

The patient is asked to indicate their perceived fatigue intensity along a 100 mm horizontal line, where '0' represents 'no fatigue' and '100', 'unbearable fatigue'

次要结局

  • a short form of stress response inventory,SRI-short form change(at 2(baseline),3(after 2 weeks of administration), 4(after 4 weeks of administration), 5(after 6 weeks of administration) and 6(follow up evaluation after 10 weeks of administration) visit)
  • insomnia severity index, ISI change(at 2(baseline),3(after 2 weeks of administration), 4(after 4 weeks of administration), 5(after 6 weeks of administration) and 6(follow up evaluation after 10 weeks of administration) visit)
  • EuroQol - 5 Dimensions - 5 Levels, EQ-5D-5L change(at 2(baseline),3(after 2 weeks of administration), 4(after 4 weeks of administration), 5(after 6 weeks of administration) and 6(follow up evaluation after 10 weeks of administration) visit)
  • ginseng subjective symptoms questionnaire change(at 2(baseline),3(after 2 weeks of administration), 4(after 4 weeks of administration) and 5(after 6 weeks of administration) visit)
  • beck depression inventory, BDI change(at 2(baseline),5(after 6 weeks of administration) and 6(follow up evaluation after 10 weeks of administration) visit)
  • derivatives of Reactive Oxygen Metabolites (d-ROMs) change(at 2(baseline) and 5(after 6 weeks of administration) visit)
  • Biological Antioxidant Potential (BAP) change(at 2(baseline) and 5(after 6 weeks of administration) visit)
  • check abnormal responses(at 1(screening),2(baseline),3(after 2 weeks of administration), 4(after 4 weeks of administration), 5(after 6 weeks of administration) and 6(follow up evaluation after 10 weeks of administration) visit)
  • fatigue severity scale change(at 2(baseline),3(after 2 weeks of administration), 4(after 4 weeks of administration), 5(after 6 weeks of administration) and 6(follow up evaluation after 10 weeks of administration) visit)
  • Chalder fatigue severity questionnaire change(at 2(baseline),3(after 2 weeks of administration), 4(after 4 weeks of administration), 5(after 6 weeks of administration) and 6(follow up evaluation after 10 weeks of administration) visit)
  • Superoxide Dismutase(SOD) change(at 2(baseline) and 5(after 6 weeks of administration) visit)
  • Stress hormone test(at 2(baseline) and 5(after 6 weeks of administration) visit)
  • Thiobarbituric Reactive Acid Substances(TBARs) change(at 2(baseline) and 5(after 6 weeks of administration) visit)

研究者

发起方
Eun Jung Kim
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Eun Jung Kim

Assistant professor

DongGuk University

研究点 (2)

Loading locations...

相似试验